Nootropics Dictionary C Words

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

C

Catecholamines

Pronunciation: kat-uh-koal-uh-meenz
Definition: A specific group of signaling molecules—acting as both hormones and neurotransmitters—that serve as the primary drivers of the body's "fight-or-flight" response and the brain's executive function. Derived from the amino acid L-Tyrosine, catecholamines are the chemical engines behind alertness, drive, and mental clarity.

The "Big Three" in Nootropics

In the world of brain-boosting, we focus on the three primary catecholamines:

  1. Dopamine: Often called the "reward chemical," it is responsible for motivation, goal-directed behavior, and fine motor control.
  2. Norepinephrine (Noradrenaline): The "vigilance" chemical. It sharpens focus, increases heart rate, and shifts the brain into a state of high-readiness.
  3. Epinephrine (Adrenaline): Primarily a survival hormone that mobilizes energy (glucose) and maximizes physical output during acute stress.

The Nootropic Connection

Most "stimulant" or "focus-based" nootropics work by modulating these chemicals. For example:

  • Precursors: Supplements like L-Tyrosine or L-Dopa provide the raw building blocks for the body to synthesize more catecholamines.
  • Reuptake Inhibitors: Compounds that keep these chemicals in the synaptic gap longer, extending the feeling of "flow" or concentration.
  • Enzyme Modulators: Substances that slow down the breakdown of catecholamines (via MAO or COMT enzymes) to maintain high mental energy.

Why They Matter

Optimal catecholamine levels represent the "sweet spot" of human performance. Too few, and you experience brain fog, lethargy, and lack of motivation (often associated with burnout). Too many, and you may experience anxiety, jitteriness, and "tunnel vision.

Proper catecholamine management is the secret to sustainable productivity. The goal is rarely to max these out, but rather to optimize their baseline to prevent the "crash" often associated with heavy stimulants.

Central Nervous System (CNS)

Pronunciation: SEN-truhl NUR-vuhs SIS-tuhm
Definition: The Central Nervous System is the primary processing suite of the vertebrate organism, comprising the encephalon (brain) and the medulla spinalis (spinal cord). It functions as the integrative hub for afferent sensory input and efferent motor output. In research, the CNS is defined by its sequestration from systemic circulation via the Blood-Brain Barrier (BBB), creating a highly regulated microenvironment for neuronal and glial activity.

The Nootropic Research Interface

In the study of cognitive enhancers (nootropics), the CNS is the primary site of pharmacological intervention. Researchers focus on several key vectors:

  • Neurochemical Modulation: The CNS houses the complex networks of neurotransmitters (e.g., Glutamate, GABA, Acetylcholine) and catecholamines. Nootropic research typically targets the upregulation of specific receptor densities or the inhibition of enzymatic breakdown within the synaptic cleft.
  • Neuroplasticity and Trophic Factors: The CNS exhibits the capacity for structural and functional reorganization. Researchers evaluate nootropics based on their ability to stimulate Brain-Derived Neurotrophic Factor (BDNF) or Nerve Growth Factor (NGF), facilitating long-term potentiation (LTP).
  • Metabolic Efficiency: The brain consumes approximately 20% of the body's total energy. Nootropic research investigates compounds that optimize mitochondrial function within the CNS or improve cerebral blood flow (vasodilation) to prevent oxidative stress.

Clinical Significance in Biohacking

From a research perspective, the CNS is governed by the principle of Homeostasis. Any exogenous substance introduced to enhance performance must be evaluated for its impact on:

  1. Tolerance/Downregulation: The system's tendency to reduce receptor sensitivity in response to chronic overstimulation.
  2. Excitotoxicity: The risk of over-activating receptors (primarily NMDA) to the point of cellular damage.
  3. Circadian Integration: How CNS stimulants or modulators affect the Suprachiasmatic Nucleus (SCN) and sleep-wake cycles.

Cerebral Circulation

Pronunciation: SERR-uh-bruhl sur-kyuh-LAY-shun
Definition: Cerebral circulation refers to the complex hemodynamic network of arteries, capillaries, and veins that facilitate the continuous delivery of oxygenated blood and glucose to the brain while simultaneously removing metabolic byproducts (such as CO² and lactic acid). It is characterized by cerebral autoregulation, a sophisticated homeostatic mechanism that maintains a constant Cerebral Blood Flow (CBF) despite fluctuations in systemic arterial pressure.

Mechanisms of Regulation

In a research context, the efficiency of cerebral circulation is governed by three primary factors:

  1. Myogenic Response: The innate ability of vascular smooth muscle to contract or dilate in response to pressure changes.
  2. Metabolic Regulation: The dilation of vessels in response to local increases in metabolic byproducts (e.g., adenosine, H+, or nitric oxide), ensuring blood is diverted to the most active neuronal regions—a process known as neurovascular coupling.
  3. The Blood-Brain Barrier (BBB): The highly selective semipermeable border that protects the brain from systemic fluctuations while managing the transport of essential molecules via the circulatory system.

The Nootropic Research Context

Cerebral circulation is often the "first responder" in cognitive enhancement. Many research compounds target the circulatory system to bypass the limitations of neuronal fatigue:

  • Rheology and Viscosity: Certain nootropics act as rheological agents, reducing blood viscosity to allow for better microcirculation in the smallest capillaries.
  • Vasodilation vs. Vasoconstriction: Research focuses on compounds that induce localized vasodilation (e.g., Vinpocetine) to increase oxygen saturation without causing systemic hypotension.
  • Neuroprotection: Optimizing circulation is a primary strategy for mitigating oxidative stress and preventing ischemia-induced damage to delicate CNS tissues.

Primary Research Metrics

  • CBF (Cerebral Blood Flow): Measured in mL/100g/min; it is the gold standard for quantifying the circulatory impact of a nootropic.
  • CPP (Cerebral Perfusion Pressure): The net pressure gradient causing blood flow to the brain (CPP = MAP - ICP).
  • Oxygen Extraction Fraction (OEF): The ratio of oxygen used by the brain relative to the oxygen delivered, indicating metabolic efficiency.

Chronic Fatigue Syndrome (CFS) / ME

Pronunciation: KRAH-nik fuh-TEEG SIN-drohm
Definition: more accurately termed Myalgic Encephalomyelitis (ME/CFS)—must move beyond the symptom of lethargy to address the underlying metabolic and neurological "failure states" that characterize the condition, is a complex, multisystemic neuro-immune disorder characterized by profound, persistent fatigue that is not alleviated by rest and is significantly exacerbated by physical or cognitive exertion (a hallmark known as Post-Exertional Malaise or PEM). In clinical research, it is increasingly viewed as a state of cellular energy failure or metabolic hypoperfusion, often involving dysregulation of the autonomic nervous system and chronic neuroinflammation.

Core Pathophysiological Research Vectors

For researchers investigating nootropics and metabolic enhancers, ME/CFS presents several distinct areas of interest:

  • Mitochondrial Dysfunction: Evidence suggests a deficit in ATP production and impaired oxygen utilization at the cellular level. Researchers study the "bioenergetic" profile of CFS patients to see if mitochondrial enhancers (e.g., CoQ10, PQQ, or NADH) can bypass the metabolic block.
  • Neuroinflammation & Microglial Activation: PET imaging research has shown widespread activation of microglia (the brain's immune cells) in CFS cohorts. This suggests that "brain fog" in CFS is an inflammatory response rather than mere cognitive fatigue.
  • HPA Axis Dysregulation: Research often finds a "blunted" cortisol response in CFS patients, indicating a breakdown in the communication between the hypothalamus, pituitary, and adrenal glands—the system responsible for the catecholamine response (stress/arousal).
  • Autonomic Instability: Many patients exhibit POTS (Postural Orthostatic Tachycardia Syndrome) or other forms of orthostatic intolerance, where cerebral circulation is compromised upon standing.

The Nootropic Research Context

In the nootropics community, ME/CFS is often studied as the "extreme baseline" for cognitive impairment. Research focuses on:

  1. Non-Stimulant Wakefulness: Traditional stimulants (like caffeine or amphetamines) often trigger a "crash" in CFS patients. Researchers look for eugeroics or adaptogens that support energy without over-taxing the CNS.
  2. Glymphatic Clearance: Investigating whether impaired waste removal during sleep contributes to the accumulation of metabolic debris in the CNS.
  3. Neuroprotection: Using antioxidants to mitigate the high levels of oxidative stress found in the blood and cerebrospinal fluid of those with the condition.

Primary Research Metrics

  • VO2 Max & 2-Day CPET: The Gold Standard for proving Post-Exertional Malaise by measuring the drop in metabolic capacity over two consecutive days.
  • Cytokine Profiling: Measuring pro-inflammatory markers (e.g., IL-6, TNF-alpha) to track systemic inflammation.
  • Cognitive Battery (CNS Vital Signs): Quantifying deficits in processing speed, executive function, and working memory.

Circadian Rhythm

Pronunciation: sur-KAY-dee-un RITH-um
Definition: An endogenous, entrainable oscillation of physiological processes that repeats approximately every 24 hours. These rhythms are driven by a hierarchical system of biological clocks, most notably the "master clock" located in the Suprachiasmatic Nucleus (SCN) of the hypothalamus. At the cellular level, these rhythms are governed by a molecular oscillator—a transcriptional-translational feedback loop involving specific "clock genes" (such as CLOCK, BMAL1, PER, and CRY).

The Chronobiological Framework

In research, circadian rhythms are not merely about sleep, but about the temporal coordination of the entire organism:

  • Photoentrainment: The process by which the SCN synchronizes the internal clock to the external environment via blue-light-sensitive retinal ganglion cells (melanopsin).
  • Peripheral Oscillators: Almost every organ and tissue possesses its own clock, which is synchronized by the SCN but can be independently influenced by "Zeitgebers" (time-givers) like food intake and temperature.
  • Hormonal Pulsatility: The rhythmic release of Melatonin (the "vampire hormone" of the dark) and Cortisol (the "awakening response" hormone) dictates the metabolic and cognitive windows of the day.

The Nootropic Research Context

The efficacy of a nootropic is often a function of when it is administered relative to the circadian phase.

  1. Chronopharmacokinetics: Circadian rhythms influence the absorption, distribution, metabolism, and excretion (ADME) of compounds. For example, certain liver enzymes follow a rhythmic expression, altering the half-life of research substances.
  2. Receptor Sensitivity: Neurotransmitter receptor density (e.g., Adenosine or Dopamine receptors) fluctuates throughout the 24-hour cycle. A nootropic administered during a "trough" of receptor sensitivity may yield a significantly different effect than one administered at the "peak."
  3. Circadian Desynchrony: Research into nootropics like Melatonin, Agomelatine, or Orexin antagonists focuses on "re-setting" the clock in cases of shift work, jet lag, or neurodegenerative-linked sleep fragmentation.
  4. Molecular Clock Modulation: Emerging research investigates "Clock-Enhancing" small molecules that target REV-ERB or CRY proteins to optimize metabolic and cognitive health directly at the genetic level.

Primary Research Metrics

  • DLMO (Dim Light Melatonin Onset): The gold standard for determining the beginning of the biological night.
  • Phase Response Curve (PRC): A graph showing the relationship between the timing of a stimulus (like a nootropic or light) and the resulting shift in the circadian clock.
  • Actigraphy: The use of non-invasive sensors to track rest/activity cycles over long-term research periods.

Research Note: When designing a protocol for a new cognitive enhancer, researchers must account for inter-individual chronotypes (e.g., "morning larks" vs. "night owls"), as a standardized dosing time may produce heterogeneous data due to differing internal clock alignments.

Concentration

Pronunciation: KON-sen-TRAY-shun
Definition:

1. Cognitive Definition (Psychological/Neurological)

In neurobiology, concentration is the executive function of directing mental resources toward a specific stimulus or task while actively inhibiting distracting "noise." Unlike simple arousal or wakefulness, concentration involves the selective allocation of limited-capacity attentional resources.

  • Mechanism: Primarily mediated by the Prefrontal Cortex (PFC) and the Dorsal Anterior Cingulate Cortex (dACC). It relies on the precise modulation of catecholamines—specifically Dopamine and Norepinephrine—which act to increase the "signal-to-noise ratio" in neuronal firing.
  • The Nootropic Interface: Research into "focus-oriented" nootropics (e.g., Modafinil or Methylphenidate) evaluates their efficacy based on their ability to prolong the "Time on Task" and reduce "Attentional Blink" or task-switching latency.

2. Pharmacological Definition (Biochemical)

In a laboratory or clinical setting, concentration refers to the abundance of a constituent (the nootropic compound) divided by the total volume of the mixture. It is the critical variable in determining the Dose-Response Curve.

  • Common Units: In research papers, this is usually expressed as Molarity (mol/L), mass concentration (mg/mL), or in blood serum as nanograms per milliliter (ng/mL).
  • The Nootropic Interface: Researchers must track the Steady-State Concentration—the point where the rate of drug administration equals the rate of elimination—to ensure the subject remains within the Therapeutic Window without reaching toxic or sub-perceptual levels.

Intersection: The Concentration-Effect Relationship

For nootropics researchers, the primary goal is to correlate Pharmacological Concentration with Cognitive Concentration. This involves analyzing:

  • Cmax (Peak Concentration): The highest concentration of a nootropic in the blood after administration. Researchers correlate this time-stamp with the peak performance in cognitive batteries.
  • The Inverted-U Hypothesis: Many nootropics exhibit a "Goldilocks" effect; where a specific concentration (C) optimizes cognitive concentration, but exceeding that concentration (C+1) leads to cognitive impairment (e.g., the jittery over-stimulation of too much caffeine).
  • Bioavailability: The fraction of the administered dose that reaches systemic circulation. This determines the actual concentration available to cross the Blood-Brain Barrier (BBB).

Primary Research Metrics

  • N-Back Task / Stroop Test: Standardized psychometric tools used to quantify the "level" of mental concentration.
  • HPLC (High-Performance Liquid Chromatography): A tool used to measure the exact chemical concentration of a compound in a research sample.
  • AUC (Area Under the Curve): Represents the total exposure to a nootropic concentration over time.

Research Note: When a subject reports "increased concentration," researchers should distinguish between Objective Concentration (measured via error rates in testing) and Subjective Focus (the user's perception of effort), as some compounds increase the feeling of focus without improving actual task accuracy.

Cognition

Pronunciation: kog-NISH-un
Definition: Cognition is the collection of distinct yet interrelated mental processes involved in the acquisition, storage, retrieval, and manipulation of information. In a neurobiological framework, cognition represents the emergent property of complex neural networks—primarily within the Cerebral Cortex and Hippocampus—integrating sensory input with stored experience to generate adaptive behavior.

The Nootropic Research Interface

In the study of cognitive enhancers, researchers do not view "cognition" as a single entity, but as a composite of several measurable domains. Nootropic intervention typically targets one or more of the following:

  • Executive Function: High-level "top-down" processing (mediated by the Prefrontal Cortex) including working memory, cognitive flexibility, and inhibitory control.
  • Memory Encoding & Consolidation: The process of converting short-term stimuli into stable long-term traces, often measured via Long-Term Potentiation (LTP).
  • Processing Speed: The rate at which the Central Nervous System (CNS) can receive, integrate, and respond to information, often limited by myelination and synaptic efficiency.
  • Attentional Control: The ability to maintain a focus on specific stimuli (sustained attention) or switch between tasks (divided attention).

Biological Drivers of Cognition

From a research perspective, the "quality" of cognition is a direct reflection of:

  1. Bioenergetics: The availability of ATP and the efficiency of mitochondrial respiration in neurons.
  2. Neurotransmitter Homeostasis: The balanced flux of Acetylcholine (learning), Glutamate (excitation), and GABA (inhibition).
  3. Neuroplasticity: The brain's structural capacity to reorganize itself in response to new information, driven by neurotrophic factors like BDNF.
  4. Cerebral Perfusion: The consistent delivery of glucose and oxygen via Cerebral Circulation.

Primary Research Metrics

Because "cognition" is an abstract construct, researchers use "proxy" measurements to quantify enhancement:

  • Psychometric Testing: Standardized batteries such as the Cambridge Neuropsychological Test Automated Battery (CANTAB) or the N-Back task.
  • Electrophysiology: Using EEG to measure "P300" wave latency, which correlates with the speed of cognitive processing.
  • Neuroimaging: Utilizing fMRI or PET scans to observe changes in regional cerebral blood flow (rCBF) during cognitively demanding tasks.

Research Note: It is a common error in "biohacking" to conflate arousal (wakefulness) with cognition. While a stimulant may increase alertness, it does not necessarily improve the accuracy or complexity of information processing. True nootropic research seeks to improve the latter without over-leveraging the former.

Coenzyme

Pronunciation: ko-EN-zyme
Definition: A coenzyme is a non-protein, organic signaling or catalytic molecule that binds to a specific enzyme (apoenzyme) to form a functionally active complex known as a holoenzyme. Unlike catalysts that remain unchanged, coenzymes often function as "intermediate carriers," transferring functional groups (such as electrons, atoms, or chemical groups) during enzymatic reactions. In the Central Nervous System, they are the essential "assistants" for the metabolic pathways that generate cellular energy and synthesize neurotransmitters.

The Nootropic Research Interface

In cognitive enhancement research, coenzymes are studied as primary targets for optimizing Bioenergetic Capacity. Most nootropic coenzymes are derivatives of B-vitamins or are involved in the mitochondrial Electron Transport Chain (ETC).

  • Redox Balance (NAD+/NADH): Nicotinamide Adenine Dinucleotide acts as a critical coenzyme in glycolysis and the Krebs cycle. Researchers evaluate NAD+ precursors (like NMN or NR) for their ability to restore the NAD+/NADH ratio, which declines with age and affects neuronal resilience.
  • Mitochondrial ATP Production: Coenzyme Q10 (Ubiquinone) is a lipid-soluble coenzyme essential for the transport of electrons between complexes I/II and III of the ETC. Research focuses on its reduced form, Ubiquinol, for superior bioavailability in crossing the blood-brain barrier to mitigate oxidative stress.
  • Neurotransmitter Synthesis: Many coenzymes serve as rate-limiting factors in the production of catecholamines. For example, Pyridoxal 5'-phosphate (PLP), the active form of Vitamin B6, is the coenzyme required by aromatic L-amino acid decarboxylase to convert L-Dopa into Dopamine and 5-HTP into Serotonin.

Mechanisms of Action in Nootropics

  1. Cofactor Saturation: Research suggests that increasing the availability of specific coenzymes can "top off" enzymatic pathways that may be running at sub-optimal speeds due to nutrient deficiencies or genetic polymorphisms (e.g., MTHFR).
  2. Bioenergetic Priming: By enhancing the efficiency of the Krebs cycle, coenzymes increase the "ATP ceiling," allowing neurons to maintain high firing rates and faster synaptic vesicle recycling.
  3. Prosthetic vs. Cosubstrate roles: Researchers distinguish between coenzymes that are tightly bound (prosthetic groups) and those that diffuse freely between enzymes (cosubstrates), as this affects the pharmacokinetics of the supplemented compound.

Primary Research Metrics

  • Enzymatic Assay: Measuring the rate of substrate-to-product conversion in the presence of varying coenzyme concentrations.
  • ATP/ADP Ratio: A proxy for the energetic state of the CNS tissue.
  • Lactate/Pyruvate Ratio: Used to evaluate mitochondrial function and the efficiency of coenzyme-dependent aerobic metabolism.

Research Note: While often grouped with vitamins, coenzymes are the physiologically active forms that the body actually utilizes. When researching nootropics, it is vital to distinguish between a "vitamin precursor" (like B3) and the "active coenzyme" (like NADH), as the latter bypasses several metabolic conversion steps, often leading to higher acute efficacy in clinical trials.

Cyclic Adenosine Monophosphate (cAMP)

Pronunciation: SIK-lik uh-DEN-uh-seen MON-oh-FOS-fayt
Definition: Cyclic Adenosine Monophosphate (cAMP) is a ubiquitous intracellular secondary messenger derived from adenosine triphosphate (ATP). It serves as a vital signal transducer for many G protein-coupled receptors (GPCRs), particularly those for catecholamines like dopamine and norepinephrine. By relaying signals from the cell surface to the interior of the neuron, cAMP initiates phosphorylation cascades that ultimately regulate gene expression and synaptic strength.

The Intracellular Signaling Cascade

In the Central Nervous System, the cAMP pathway is the primary bridge between acute stimulation and long-term adaptation:

  1. Synthesis: Upon ligand binding to a Gs-coupled receptor, the enzyme adenylyl cyclase is activated, converting ATP into cAMP.
  2. Activation: cAMP binds to and activates Protein Kinase A (PKA).
  3. Translocation: Activated PKA translocates to the nucleus, where it phosphorylates the cAMP Response Element-Binding protein (CREB).
  4. Transcription: Phosphorylated CREB binds to DNA sequences, triggering the transcription of genes responsible for neuroplasticity, such as Brain-Derived Neurotrophic Factor (BDNF).

The Nootropic Research Context

cAMP is often referred to as a "molecular switch" for memory. Research into cognitive enhancement focuses on maximizing the duration and intensity of the cAMP signal:

  • Long-Term Potentiation (LTP): cAMP is essential for the late phase of LTP, the process by which synaptic connections are strengthened. Increasing cAMP levels is a primary strategy for improving memory encoding and consolidation.
  • Phosphodiesterase (PDE) Inhibition: cAMP is naturally broken down by enzymes called phosphodiesterases (specifically PDE4 in the brain). Nootropics such as Luteolin or the research chemical Rolipram function as PDE inhibitors, preventing the degradation of cAMP and effectively "turning up the volume" of the signal.
  • Adenylyl Cyclase Activation: Compounds like Forskolin (from Coleus forskohlii) directly stimulate adenylyl cyclase, bypassing the receptor to increase cAMP concentrations.
  • The CILTEP Framework: Researchers often study "Chemically Induced Long-Term Potentiation" (CILTEP) stacks, which combine a PDE4 inhibitor with a cAMP stimulant to induce a sustained state of heightened synaptic plasticity.

Primary Research Metrics

  • FRET (Förster Resonance Energy Transfer): Used in live-cell imaging to visualize real-time cAMP dynamics in neurons.
  • Radioimmunoassay (RIA) / ELISA: Quantitative methods used to measure AMP concentrations in homogenized brain tissue or cerebrospinal fluid.
  • CREB Phosphorylation (pCREB) Levels: Used as a proxy for successful cAMP signaling and downstream genomic activation.

Research Note: While increasing cAMP is a powerful tool for memory, it follows a bell-shaped curve. Excessively high levels of cAMP in the prefrontal cortex can actually impair executive function and focus—a phenomenon often seen in acute stress responses. Therefore, the goal of cAMP-focused nootropics is precise modulation rather than maximal stimulation.

Cycling

Pronunciation: sy-kling
Definition: Cycling is a structured administration protocol characterized by alternating periods of active substance use ("on-cycle") and cessation ("off-cycle"). In research, the primary objective of cycling is the prevention of tachyphylaxis—the rapid decrease in response to a drug after repeated doses—by allowing the Central Nervous System (CNS) to return to its endogenous homeostatic baseline.

Mechanistic Rationale

For researchers, the necessity of cycling is driven by several neurobiological feedback loops:

  • Receptor Downregulation: Chronic exposure to an exogenous ligand (a nootropic) often leads to a reduction in the density or sensitivity of its target receptors (p). Cycling provides a "washout period" that allows for receptor up-regulation and the restoration of normal binding affinity.
  • Enzymatic Induction: Some compounds may induce the overproduction of metabolic enzymes (e.g., Cytochrome P450 or COMT), leading to accelerated clearance rates and diminished Cmax over time.
  • Neurotransmitter Depletion: Nootropics that act as releasing agents (e.g., certain stimulants) may exhaust the presynaptic stores of neurotransmitters like Dopamine or Acetylcholine. Off-cycles are essential to allow for the re-synthesis and re-sequestration of these chemical messengers.

Standard Research Protocols

Cycling strategies vary based on the half-life and mechanism of the compound:

  • Circadian Cycles (The 5:2 Method): Five days of administration followed by a two-day cessation (usually weekends). Common for focus-oriented nootropics to prevent habituation.
  • Periodic Blocks (The 3:1 Method): Three weeks of daily use followed by one full week of washout. Often used for adaptogens or compounds that require cumulative loading.
  • Seasonal/Intermittent Cycles: Extended use for several months followed by a one-month cessation, typically used for compounds that influence structural neuroplasticity (e.g., BDNF-mimetics).

Clinical Significance in Nootropics

From a biohacking and research perspective, cycling serves as a diagnostic tool. By implementing a washout period, researchers can distinguish between:

  • Direct Pharmacological Benefit: Improvements maintained only during active use.
  • Trophic Legacy Effects: Sustained cognitive gains that persist during the off-cycle, indicating permanent or semi-permanent structural changes.
  • Baseline Drift: Subtle shifts in the subject’s cognitive baseline that may be masked by the "noise" of continuous stimulation.

Research Note: Failure to implement cycling in long-term longitudinal studies can lead to "pharmacological dependency," where the CNS adjusts its homeostatic set-point so drastically that the subject experiences a significant cognitive deficit (a "crash") upon cessation, rather than simply returning to their pre-research baseline.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z